JANX (STOCKS)
Janux Therapeutics, Inc. Common Stock
$13.740000
+0.180000 (+1.33%)
Prev close: $13.560000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David Campbell
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $838.54M
- Employees
- 103
- P/E (TTM)
- -7.46
- P/B (TTM)
- 0.88
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $13.73M |
| Nonoperating Income/Loss | $42.51M |
| Research and Development | $127.65M |
| Operating Income/Loss | -$156.98M |
| Income/Loss From Continuing Operations After Tax | -$114.48M |
| Income/Loss From Continuing Operations Before Tax | -$114.48M |
| Net Income/Loss | -$114.48M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$114.48M |
| Net Income/Loss Available To Common Stockholders, Basic | -$114.48M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.84 |
| Diluted Earnings Per Share | -$1.84 |
| Basic Average Shares | 186,652,023 |
| Diluted Average Shares | 186,652,023 |
| Assets | $1.03B |
| Current Assets | $1.00B |
| Accounts Receivable | $35.00M |
| Other Current Assets | $967.05M |
| Noncurrent Assets | $26.18M |
| Fixed Assets | $3.55M |
| Other Non-current Assets | $22.63M |
| Liabilities | $86.69M |
| Current Liabilities | $58.92M |
| Accounts Payable | $3.38M |
| Wages | $2.25M |
| Other Current Liabilities | $53.29M |
| Noncurrent Liabilities | $27.78M |
| Equity | $941.54M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $941.54M |
| Liabilities And Equity | $1.03B |
| Net Cash Flow From Operating Activities | -$77.55M |
| Net Cash Flow From Operating Activities, Continuing | -$77.55M |
| Net Cash Flow From Investing Activities | $47.70M |
| Net Cash Flow From Investing Activities, Continuing | $47.70M |
| Net Cash Flow From Financing Activities | $7.94M |
| Net Cash Flow From Financing Activities, Continuing | $7.94M |
| Net Cash Flow | -$21.92M |
| Net Cash Flow, Continuing | -$21.92M |
| Comprehensive Income/Loss | -$117.66M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$117.66M |
| Other Comprehensive Income/Loss | -$3.18M |